Lipid IVa (High Purity Precursor of LPS)

Description

Lipid IVa (High Purity)
Catalog number: MDP0892
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 0.1 mg
Molecular Weight or Concentration: 1405.7 g/mol
Supplied as: Neat
Applications: biosynthetic precursor of Lipopolysaccharides (LPS)
Storage: -20°C
Keywords: lipid IV(A), Lipid A disaccharide bisphosphate, 2,3,2’3′-Tetrakis(3-hydroxytetradecanoyl)-D-glucosaminyl-1,6-beta-D-glucosamine 1,4′-bisphosphate, 2,3,2’3′-Tetrakis(beta-hydroxymyristoyl)-D-glucosaminyl-1,6-beta-D-glucosamine 1,4′-bisphosphate
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.
Indication for Use:This product is for Research Use Only. This product is NOT for human or animal use.

References:
1: Shi J, Zhao Y, Wang Y, Gao W, Ding J, Li P, Hu L, Shao F. Inflammatory
caspases are innate immune receptors for intracellular LPS. Nature. 2014 Oct
9;514(7521):187-92.

2: Scior T, Alexander C, Zaehringer U. Reviewing and identifying amino acids of
human, murine, canine and equine TLR4 / MD-2 receptor complexes conferring
endotoxic innate immunity activation by LPS/lipid A, or antagonistic effects by
Eritoran, in contrast to species-dependent modulation by lipid IVa. Comput
Struct Biotechnol J. 2013 Apr 5;5:e201302012.

3: Ogura N, Muroi M, Sugiura Y, Tanamoto K. Lipid IVa incompletely activates
MyD88-independent Toll-like receptor 4 signaling in mouse macrophage cell lines.
Pathog Dis. 2013 Apr;67(3):199-205.

4: Bowen WS, Gandhapudi SK, Kolb JP, Mitchell TC. Immunopharmacology of lipid A
mimetics. Adv Pharmacol. 2013;66:81-128.

5: Saitoh S, Akashi S, Yamada T, Tanimura N, Kobayashi M, Konno K, Matsumoto F,
Fukase K, Kusumoto S, Nagai Y, Kusumoto Y, Kosugi A, Miyake K. Lipid A
antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like
receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization. Int Immunol.
2004 Jul;16(7):961-9.

6: Takasawa K, Kano R, Maruyama H, Hasegawa A, Kamata H. The antagonist activity
of lipid IVa on the stimulation by lipid A of TNF-alpha production from canine
blood mononuclear cells. Vet Immunol Immunopathol. 2011 Sep 15;143(1-2):167-9.

7: Kovach NL, Yee E, Munford RS, Raetz CR, Harlan JM. Lipid IVA inhibits
synthesis and release of tumor necrosis factor induced by lipopolysaccharide in
human whole blood ex vivo. J Exp Med. 1990 Jul 1;172(1):77-84.

8: Muroi M, Tanamoto K. Structural regions of MD-2 that determine the agonist-
antagonist activity of lipid IVa. J Biol Chem. 2006 Mar 3;281(9):5484-91.

9: Resman N, Oblak A, Gioannini TL, Weiss JP, Jerala R. Tetraacylated lipid A
and paclitaxel-selective activation of TLR4/MD-2 conferred through hydrophobic
interactions. J Immunol. 2014 Feb 15;192(4):1887-95.
10: Scior T, Lozano-Aponte J, Figueroa-Vazquez V, Yunes-Rojas JA, Zähringer U,
Alexander C. Three-dimensional mapping of differential amino acids of human,
murine, canine and equine TLR4/MD-2 receptor complexes conferring endotoxic
activation by lipid A, antagonism by Eritoran and species-dependent activities
of Lipid IVA in the mammalian LPS sensor system. Comput Struct Biotechnol J.
2013 Aug 8;7:e201305003.

Products Related to Lipid IVa (High Purity) : Peptides